SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Intensity Therapeutics, Inc. (INTS) has a negative trailing P/E of -6.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.03%, forward earnings yield 227.27%.
Criteria proven by this page:
- VALUE (35/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -6.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -15.03%).
- Forward P/E 0.4 — analysts expect a return to profitability with estimated EPS of $12.00 for FY2030.
- Trailing Earnings Yield -15.03% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 227.27% as earnings recover.
- Analyst consensus target $5.00 (-5.7% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 41/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — INTS
Valuation Multiples
P/E (TTM)-6.7
Forward P/E0.4
PEG RatioN/A
Forward PEGN/A
P/B Ratio6.50
P/S Ratio0.00
EV/EBITDA0.1
Per Share Data
EPS (TTM)$-0.86
Forward EPS (Est.)$12.00
Book Value / Share$0.88
Revenue / Share$0.00
FCF / Share$-0.68
Yields & Fair Value
Earnings Yield-15.03%
Forward Earnings Yield227.27%
Dividend Yield0.00%
Analyst Target$5.00 (-5.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-3.9 |
0.00 |
2.63 |
0.00 |
- |
| 2020 |
-3.4 |
-0.28 |
-13.04 |
0.00 |
- |
| 2021 |
-2.6 |
-0.08 |
-2.34 |
0.00 |
- |
| 2022 |
-2.7 |
0.62 |
-1.35 |
0.00 |
- |
| 2023 |
-6.2 |
0.16 |
4.98 |
0.00 |
- |
| 2024 |
-1.5 |
0.10 |
8.39 |
0.00 |
- |
| 2025 |
-12.0 |
0.17 |
11.72 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.40 |
$0.00 |
$-5.23M |
- |
| 2020 |
$-0.45 |
$0.00 |
$-5.96M |
- |
| 2021 |
$-0.60 |
$0.00 |
$-7.89M |
- |
| 2022 |
$-0.57 |
$0.00 |
$-7.45M |
- |
| 2023 |
$-1.38 |
$0.00 |
$-10.54M |
- |
| 2024 |
$-1.17 |
$0.00 |
$-16.27M |
- |
| 2025 |
$-8.56 |
$0.00 |
$-11.61M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-3.94 |
$-4.32 – $-3.56 |
$3M |
$3M – $3M |
2 |
| 2027 |
$-3.80 |
$-4.56 – $-3.04 |
$351K |
$351K – $351K |
2 |
| 2028 |
$-3.65 |
$-5.14 – $-2.18 |
$4.23M |
$4.23M – $4.23M |
3 |
| 2029 |
$-0.25 |
$-0.25 – $-0.25 |
$59.52M |
$59.52M – $59.52M |
1 |
| 2030 |
$12.00 |
$12.00 – $12.00 |
$129.17M |
$129.17M – $129.17M |
1 |
